Celldex TherapeuticsCLDX
CLDX
About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Employees: 186
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
19% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0.15% less ownership
Funds ownership: 111.07% [Q4 2024] → 110.92% (-0.15%) [Q1 2025]
6% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 31
2% less funds holding
Funds holding: 174 [Q4 2024] → 171 (-3) [Q1 2025]
28% less capital invested
Capital invested by funds: $1.86B [Q4 2024] → $1.34B (-$525M) [Q1 2025]
65% less call options, than puts
Call options by funds: $2.13M | Put options by funds: $6.12M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$31
46%
upside
Avg. target
$45
113%
upside
High target
$64
201%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 135%upside $50 | Buy Reiterated | 13 Jun 2025 |
UBS Trung Huynh | 79%upside $38 | Buy Maintained | 9 May 2025 |
Goldman Sachs Richard Law | 46%upside $31 | Neutral Maintained | 9 May 2025 |
Morgan Stanley Judah Frommer | 102%upside $43 | Overweight Maintained | 9 May 2025 |
Canaccord Genuity Edward Nash | 201%upside $64 | Buy Initiated | 28 Apr 2025 |
Financial journalist opinion
Based on 4 articles about CLDX published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.
Neutral
GlobeNewsWire
2 days ago
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.
Neutral
GlobeNewsWire
4 days ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland.
Neutral
GlobeNewsWire
1 week ago
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Negative
Zacks Investment Research
1 month ago
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update.
Neutral
GlobeNewsWire
1 month ago
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).
Neutral
GlobeNewsWire
3 months ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Neutral
GlobeNewsWire
3 months ago
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing -
Neutral
GlobeNewsWire
3 months ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 -
Charts implemented using Lightweight Charts™